Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects

Overview of attention for article published in PLOS ONE, June 2013

Altmetric Badge

Mentioned by

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 15,936 followers.

The results of the TB group’s recent clinical trial of their vaccine, MVA85A, has been published in PLoSONE. http://t.co/jNWkbXsHDH

#PLOSONE: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Compara... http://t.co/fAVry3p3yV